Lens epithelial cells senescence in cataract pathogenesis and emerging therapeutic opportunities

Mar 20, 2026Frontiers in cell and developmental biology

Aging of lens surface cells in cataract development and new treatment possibilities

AI simplified

Abstract

Lens epithelial cells (LECs) senescence may drive cataract formation through chronic stressors.

  • LECs undergo stable cell cycle arrest and develop a when exposed to chronic stressors.
  • Impaired autophagic flux in senescent LECs compromises their function and disrupts lens homeostasis.
  • The pro-inflammatory microenvironment created by senescent LECs could accelerate cataract progression.
  • Senolytic agents like Dasatinib and Quercetin are designed to selectively eliminate senescent cells.
  • Senomorphic agents such as Metformin and Rapamycin aim to restore cellular homeostasis by modulating the secretory phenotype.
  • Ocular drug delivery barriers present challenges for the effective treatment of senescent LECs.

AI simplified

Key numbers

45% of blindness cases
Cataracts' global burden
Cataracts account for a significant percentage of global blindness.
Improved lens transparency in aged rats
Senolytic therapy effectiveness
Combination therapy of Dasatinib and Quercetin showed positive effects on lens clarity.
Less than 5% ocular bioavailability
Ocular drug delivery challenge
Current drug delivery methods often fail to penetrate the eye effectively.

Full Text

What this is

  • Cataracts, primarily caused by lens epithelial cells (LECs) senescence, remain a leading cause of visual impairment globally.
  • Chronic stressors like oxidative damage and UV exposure drive LECs into a senescent state, disrupting lens function.
  • Recent advances in targeting senescent LECs with agents like and offer promising therapeutic avenues.
  • This review advocates for a shift from solely surgical interventions to disease-modifying therapies that address the underlying cellular mechanisms.

Essence

  • LECs senescence significantly contributes to cataract formation, driven by chronic stressors. Targeting this senescence through pharmacological means presents new opportunities for cataract management beyond surgery.

Key takeaways

  • LECs senescence is a central mechanism in cataract pathogenesis, characterized by stable cell-cycle arrest and the secretion of pro-inflammatory factors.
  • Therapeutic strategies targeting LECs senescence, including and , can potentially delay cataract progression by preserving lens transparency.
  • Challenges in drug delivery to the eye complicate the translation of these therapies from research to clinical practice, necessitating innovative delivery methods.

Caveats

  • The review emphasizes the need for further research on the heterogeneity of senescent LECs to develop targeted therapies.
  • Current models used to study LEC senescence may not fully replicate clinical conditions, highlighting the need for improved experimental designs.

Definitions

  • senescence-associated secretory phenotype (SASP): A complex of pro-inflammatory factors secreted by senescent cells that can affect surrounding tissues.
  • senolytics: Drugs that selectively induce death in senescent cells to alleviate age-related pathologies.
  • senomorphics: Agents that modulate the SASP without killing senescent cells, aiming to restore tissue homeostasis.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free